Governance and funding

The Pediatric Praziquantel Consortium uses an innovative approach that engages new partners as needed, to ensure rapid development of a successful new pediatric praziquantel formulation. The model is built on a solid governance structure:

  • A core project team of experienced leading scientists designs, drives and implements the development program. Subteams are in place to tackle specific areas of responsibilities in more detail (e.g. CMC, clinical, regulatory, communication and others).
  • The project team reports to a Consortium Board [hyperlink to Board page], chaired by Merck KGaA, which is composed by high level executives from various consortium partners. The board meets on a bi-annual basis to review program progress and to provide strategic guidance.
  • Further support comes from a scientific advisory panel of renowned international experts in schistosomiasis, pediatrics and other related disciplines. This dynamic panel meets on a regular basis during so-called ‘expert meetings’ to assess and review scientific aspects relevant to the project phase.  The Consortium also greatly benefits from the expertise of non-governmental organizations, like the WHO.  Visit our timeline for an overview of the different expert meetings.

Funding

Apart from contributions by the partners themselves, the Consortium continuously seeks external funding to support the overall development program. We were awarded grants from the Bill & Melinda Gates Foundation in 2013, and the Global Health Innovative Technology (GHIT) Fund in 2014 and 2015.